Drugs in Dev. Musculoskeletal
Phase I
United Kingdom 
Lead Product(s) : MEDI7352
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 25, 2021
Lead Product(s) : MEDI7352
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naquinate
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Haoma Medica Completes First-in-Human Trial for NaQuinate
Details : The first-in-human trial initiated last year in healthy adults studied single and multiple doses of NaQuinate. The primary objective was to assess the safety, tolerability and pharmacokinetics.
Product Name : Osteopura
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 26, 2020
Lead Product(s) : Naquinate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naquinate
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NaQuinate synergized the body’s normal response to loading to generate significant increases in cortical bone mass (increased cross sectional area, reductions in cortical porosity) and J-score (predictor of bone strength) compared to loading alone.
Product Name : Osteopura
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2020
Lead Product(s) : Naquinate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naquinate
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of NaQuinate in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2019
Lead Product(s) : Naquinate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LEVI-04
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Hammersmith Medicines Research | MAC Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 24, 2017
Lead Product(s) : LEVI-04
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Hammersmith Medicines Research | MAC Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 12, 2014
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MEDI-578
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 22, 2010
Lead Product(s) : MEDI-578
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
